Vande Woude; George F.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Vande Woude; George F..The latest application filed is for "biomarker and method for predicting sensitivity to met inhibitors".

Company Profile

0.12.12

Vande Woude; George F. - Ada MI US
Vande Woude, George F - Ada MI
Vande Woude; George F. - Berryville VA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Mig-6 knockout mice and elucidation of association of Mig-6 with early onset degenerative joint disease and role as a tumor suppressor Grant 8,466,339 - Zhang , et al. June 18, 2	2013-06-18
Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods Grant 8,309,315 - Cao , et al. November 13, 2	2012-11-13
Biomarker and Method for Predicting Sensitivity to MET Inhibitors App 20120100157 - Vande Woude; George F. ; et al.	2012-04-26
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) Grant 7,968,762 - Vande Woude , et al. June 28, 2	2011-06-28
Mig-6 Knockout Mice And Elucidation Of Association Of Mig-6 With Early Onset Degenerative Joint Disease And Role As A Tumor Suppressor App 20110099644 - Zhang; Yu-Wen ; et al.	2011-04-28
Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods Grant 7,892,770 - February 22, 2	2011-02-22
c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity Grant 7,872,117 - Shinomiya , et al. January 18, 2	2011-01-18
Monoclonal Antibody Which Binds Met In Formalin-fixed And Paraffin-embedded Tissues And Related Methods App 20100285504 - Cao; Boliang ; et al.	2010-11-11
Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma Grant 7,612,035 - Koo , et al. November 3, 2	2009-11-03
Monoclonal Antibody Which Binds Met In Formalin-Fixed and Paraffin-Embedded Tissues and Related Methods App 20090053737 - Cao (Brian); Boliang ; et al.	2009-02-26
Immune-Compromised Transgenic Mice Expressing Human Hepatocyte Growth Factor (Hhgf) App 20080196110 - Vande Woude; George F. ; et al.	2008-08-14
Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets App 20070297980 - Xie; Qian ; et al.	2007-12-27
Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor App 20070020234 - Vande Woude; George F. ; et al.	2007-01-25
Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma App 20050267012 - Koo, Han-Mo ; et al.	2005-12-01
Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor App 20050118165 - Hay, Rick V. ; et al.	2005-06-02
Anthrax lethal factor inhibits tumor growth and angiogenesis App 20040136975 - Duesbery, Nicholas S ; et al.	2004-07-15
Met proto-oncogene and a method for predicting breast cancer progression Grant 6,673,559 - Tsarfaty , et al. January 6, 2	2004-01-06
Molecules that influence pathogen resistance App 20030017985 - Taylor, Gregory Alan ; et al.	2003-01-23
Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma App 20020054869 - Koo, Han-Mo ; et al.	2002-05-09
Hepatic growth factor receptor is the MET proto-oncogene Grant 5,648,273 - Bottaro , et al. July 15, 1	1997-07-15
Methods of identifying drugs with selective effects against cancer cells Grant 5,645,988 - Vande Woude , et al. July 8, 1	1997-07-08
Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines Grant 5,362,716 - Kmiecik , et al. November 8, 1	1994-11-08
LTR-Vectors Grant 4,405,712 - Vande Woude , et al. September 20, 1	1983-09-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.